114636-33-8

Basic information

• Product Name: (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE&
• Synonyms: (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE&;(R)-1-BENZLY-3-ACETYLAMINOPYRROLIDINE;N-((R)-1-Benzylpyrrolidin-3-yl)acetamide;(R)-(+)-1-Benzyl-3-acetylaminopyrrolidine;N-[(3R)-1-benzylpyrrolidin-3-yl]acetamide
• CAS NO: 114636-33-8
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 218.29482
• Product Categories: Chiral Building Blocks;Heterocyclic Building Blocks;Pyrrolidines
• Mol File: 114636-33-8.mol

Chemical Properties

• Boiling Point: 307-308 °C760 mm Hg(lit.)
• Flash Point: 110 °C
• Appearance: /
• Density: 1.139 g/mL at 25 °C(lit.)
• Vapor Pressure: 3.33E-06mmHg at 25°C
• Refractive Index: n20/D 1.5470(lit.)
• Storage Temp.: 2-8°C
• PKA: 15.89±0.20(Predicted)
• CAS DataBase Reference: (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE&(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE&(114636-33-8)
• EPA Substance Registry System: (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE&(114636-33-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 114636-33-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
(R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE& is used as a key intermediate in the synthesis of pharmaceutical drugs due to its unique stereochemistry and functional groups. It plays a crucial role in the development of new drugs for various medical conditions.
Used in the Synthesis of Bioactive Molecules:
In the field of medicinal chemistry, (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE& is employed as a building block for the creation of new chemical entities. Its structural features make it an ideal candidate for the synthesis of bioactive molecules with potential therapeutic applications.
Used in Drug Discovery:
(R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE& is utilized in drug discovery processes to identify and optimize new drug candidates. Its unique properties allow researchers to explore its potential in treating a range of diseases and conditions.
Used in the Production of Bioactive Molecules:
In the chemical industry, (R)-(+)-BENZYL-3-ACETYLAMINOPYRROLIDINE& is used as a valuable intermediate in the production of bioactive molecules. Its presence in the synthesis process contributes to the development of innovative pharmaceutical compounds with improved efficacy and safety profiles.

InChI:InChI=1/C13H18N2O/c1-11(16)14-13-7-8-15(10-13)9-12-5-3-2-4-6-12/h2-6,13H,7-10H2,1H3,(H,14,16)/t13-/m1/s1

Upstream product

• 108-24-7 acetic anhydride 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 
• 114636-29-2 (3S)-3-azido-1-(phenylmethyl)pyrrolidine 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 114715-35-4 (R)-3-methanesulfonyloxy-1-(phenylmethyl)-pyrrolidine 
• 114715-39-8 (R)-1-benzyl-3-aminopyrrolidine 

Downstream Products

• 114715-37-6 (3'R)-7-(3'-aminopyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride 
• 115445-21-1 (R)-1-benzyl-N-ethylpyrrolidine-3-amine 

Relevant articles and documents

Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor

A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib's core structure, (3R,4R)-3-amino-4-methylpiperidine. From the new core structures, we selected (R)-N-methyl-N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a scaffold for further SAR studies. From biochemical enzyme assays and liver microsomal stability tests, (R)-3-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile (6) was chosen for further in vivo test through oral administration. Compound 6 showed improved selectivity for JAK1 compared to that of tofacitinib (IC50 11, 2.4 × 102, 2.8 × 103, and 1.1 × 102 nM for JAK1, JAK2, JAK3, and TYK2, respectively). In CIA and AIA model tests, compound 6 exhibited similar efficacy to tofacitinib citrate.

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and/or diabetes.

Asymmetric Synthesis and Properties of the Enantiomers of the Antibacterial Agent 7-(3-Aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic Acid Hydrochloride

Compound 1 is a potent member of the quinoloecarboxylic acid class of antibacterial agents and is currently undergoing clinical evaluation.We have developed efficient asymmetric syntheses of the enantiomers of this agent.The S-(+) enantiomer 1a is 1-2 log2 dilutions more active than the R-(-) enantiomer 1b against aerobic bacteria and 1-2 or more log2 dilutions more active against anaerobic bacteria in vitro.The enantiomer 1a shows significantly better in vivo activity in a Pseudomonas aeruginosa mouse protection model compared to racemic 1.Coupled with the improved solubility profile of 1a relative to racemic material, these features may be of practical significance from a clinical standpoint.